1. Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011;17:4834–43. doi: 10.1158/1078-0432.CCR-10-2962 .
2. Nieder C, Spanne O, Mehta MP, Grosu AL, Geinitz H. Presentation, patterns of care, and survival in patients with brain metastases: what has changed in the last 20 years? Cancer. 2010. doi: 10.1002/cncr.25707 .
3. Graesslin O, Abdulkarim BS, Coutant C, Huguet F, Gabos Z, Hsu L, et al. Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncol. 2010;28:2032–7. doi: 10.1200/JCO.2009.24.6314 .
4. • Pivot XSV, Zurawski B, Allerton R, Fabi A, Ciruelos E, Parikh R, et al., editors. CEREBEL (EGF111438): an open label randomized phase III study comparing the incidence of CNS metastases in patients (pts) with HER2+ metastatic breast cancer (MBC), treated with lapatinib plus capecitabine (LC) vs trastuzumab plus capecitabine (TC). Vienna: The Annual Meeting of the European Society for Medical Oncology; 2012. This study showed a high prevalence of asymptomatic BM among HER2+ BC patients.
5. Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res. 2007;13:1648–55. doi: 10.1158/1078-0432.CCR-06-2478 .